SCHEMBL9611824

SCHEMBL9611824

C1=C\Cc2ccccc2-c2c(cc(-c3ccc4cc(-c5cn6ccccc6n5)ccc4c3)c3ccccc23)C\C=C/1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 13/20 0.44
▸ NPC1 O15118 12/20 0.44
▸ ALDH1A1 P00352 10/20 0.44
▸ SMN1; SMN2 Q16637 8/20 0.44
▸ PKM P14618 5/20 0.44
▸ MAPK1 P28482 2/20 0.44
▸ KDM4E B2RXH2 10/20 0.44
▸ GFER P55789 2/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ EPHX2 P34913 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ MIF P14174 1/20 0.44
▸ MAPT P10636 4/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ TP53 P04637 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ POLB P06746 3/20 0.41
▸ NFKB1 P19838 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9611770 0.78 RAB9A (0.48) RAB9ANPC1ALDH1A1SMN1; SMN2PKM
SCHEMBL13454289 0.78 RAB9A (0.61) RAB9ANPC1ALDH1A1SMN1; SMN2PKM
SCHEMBL9976929 0.77 RAB9A (0.54) RAB9ANPC1ALDH1A1SMN1; SMN2PKM
SCHEMBL19726974 0.75 RAB9A (0.58) RAB9ANPC1ALDH1A1SMN1; SMN2PKM
SCHEMBL13454262 0.74 RAB9A (0.57) RAB9ANPC1ALDH1A1SMN1; SMN2PKM
SCHEMBL13454266 0.73 RAB9A (0.56) RAB9ANPC1ALDH1A1SMN1; SMN2PKM
SCHEMBL11885965 0.73 RAB9A (0.47) RAB9ANPC1ALDH1A1SMN1; SMN2PKM
SCHEMBL9976895 0.73 RAB9A (0.52) RAB9ANPC1ALDH1A1SMN1; SMN2PKM
SCHEMBL971818 0.72 RAB9A (0.54) RAB9ANPC1ALDH1A1SMN1; SMN2PKM
SCHEMBL13325743 0.72 RAB9A (0.68) RAB9ANPC1ALDH1A1SMN1; SMN2PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120132899-A1 NITROGENATED HETEROCYCLIC RING DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME IDEMITSU KOSAN CO., LTD. (JP) 2012-05-31 — — US disclosed
US-20120132899-A1 NITROGENATED HETEROCYCLIC RING DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME IDEMITSU KOSAN CO., LTD. (JP) 2012-05-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120132899-A1 NITROGENATED HETEROCYCLIC RING DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME H1-2, L1CAM, H1-0 RAB9A 1663/4885NPC1 1609/4885ALDH1A1 191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback